Biopharmaceuticals Packaging Companies & Business Growth Insights - Corporate Milestones, Corporate Growth and Development Strategy, Intellectual Property (IP) Portfolio Management, Competitive Performance Benchmarking, Executive Vision

Biopharmaceuticals Packaging Market Size and Companies

The global biopharmaceuticals packaging market was valued at USD 19.37 billion in 2023 and is projected to reach USD 49.98 billion by 2034, registering a CAGR of 9% from 2024 to 2034. The market growth is attributed to the increasing pharmaceutical outsourcing and increasing emphasis on recyclable packaging.

The competitive landscape of the biopharmaceutical packaging market is dominated by established industry giants such as Cipla, Gerresheimer, Multipharma, Bormioli Pharma, Febelco Group, and Merck KGaA collaborate with LOG Pharma Packaging, W.L Gore & Associates, Inc., West Pharmaceutical Services, Inc., Pacific Vial Manufacturing, and Piramal Glass Private Limited, Stevanato Group, Shandong Pharmaceutical Glass Co, and Chongqing Zhengchuan Pharmaceutical Packaging Co. These giants compete with upstart direct-to-consumer firms that use digital platforms to gain market share. Key competitive characteristics include product innovation, sustainable practices, and the ability to respond to changing consumer tastes.

Cipla is a prominent global pharmaceutical business dedicated to offering inexpensive and accessible healthcare solutions. Cipla's focus in the biopharmaceutical packaging business is likely to be on innovation and cost effectiveness. They may spend in R&D to develop unique packaging methods that address the special needs of biopharmaceutical goods while remaining affordable to patients and healthcare providers.

For Instance,

• In January 2024, A strategic partnership has been announced by Cipla (EU) Limited, UK, a wholly owned subsidiary of Cipla Limited, also known as Cipla, with Kemwell Biopharma Private Limited (via its subsidiary Kemwell Biopharma UK Limited) and Manipal Education & Medical Group to establish a joint venture in the United States.

Gerresheimer is an established supplier of high-quality glass and plastic packaging products for the pharmaceutical and healthcare industries. In the biopharmaceutical packaging industry, Gerresheimer is likely to focus on supplying premium packaging solutions that match the high quality and regulatory requirements of biopharmaceutical goods.

For Instance,

• In January 2024, Manufacturer Gerresheimer, which supplies the pharmaceutical and life science industries, plans to expand its production operations in Peachtree City with an investment of over $88 million, bringing with it the creation of over 200 new jobs in Fayette County.

Multipharma is a pharmaceutical firm that offers a diverse variety of healthcare goods and services. In the biopharmaceutical packaging market, Multipharma may take a varied strategy, providing packaging solutions targeted to different segments and applications within the industry.

For Instance,

• A new distribution deal between MultiPharma and Glenvale Packaging enabled it to expand across the UK and Ireland. 

Bormioli Pharma is a prominent developer of glass and plastic packaging solutions tailored to the pharmaceutical and biopharmaceutical sectors. Bormioli Pharma's priorities in the biopharmaceutical packaging market are anticipated to be product innovation, sustainability, and customer centricity.

For Instance,

• In May 2023, the open innovation platform Desall.com and the pharmaceutical packaging and medical device manufacturer Bormioli Pharma have partnered to launch two new competitions.

Biopharmaceuticals Packaging Market Player

• Cipla
• Gerresheimer
• Multipharma
• Bormioli Pharma
• Febelco Group
• Merck KGaA (collaborates with LOG Pharma Packaging)
• LOG Pharma Packaging
• W.L Gore & Associates, Inc.
• West Pharmaceutical Services, Inc.
• Pacific Vial Manufacturing
• Piramal Glass Private Limited
• Stevanato Group
• Shandong Pharmaceutical Glass Co.
• Chongqing Zhengchuan Pharmaceutical Packaging Co.

Recent Developments

• In October 2024, a contract development and manufacturing organization (CDMO), Samsung Biologics launched a new high-concentration formulation platform, S-HiCon to enhance the manufacturing and development of high-dose drugs. 
• In July 2023, the BioPharmaPro family of innovative services, materials, and products was launched by Trelleborg Healthcare and Medical for fluid path single-use equipment. The aim behind this launch was to accelerate the advancement of life-changing therapies.